Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer

S. Di Cosimo, A. Alimonti, Gia Ferretti, I. Sperduti, P. Carlini, P. Papaldo, A. Fabi, A. Gelibter, M. Ciccarese, D. Giannarelli, M. Mandalà, M. Milella, E. M. Ruggeri, F. Cognetti

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: The aim of this study was to characterize the factors associated with chemotherapy-induced amenorrhea (CIA) and to examine whether the phase of the menstrual cycle at chemotherapy start could affect the rate of CIA in premenopausal women with early breast cancer. Methods: CIA was defined as the cessation of menses for at least 3 months during or after chemotherapy. Menstrual phase was defined as days 1-6, follicular phase as days 7-14, luteal phase as days 15-20 and premenstrual phase as days 21-28. Univariate and multivariate predictors of CIA were examined. Results: Among 111 premenopausal women, univariate analysis showed a higher incidence of CIA in patients treated in the follicular phase rather than in other menstrual cycle phases (67.6% compared with 45.5%; P = 0.03). The rate of CIA increased with age: 65.2% and 45.8% in patients aged >42 and ≤42 years, respectively (P = 0.05). Upon multivariate analysis these differences remained statistically significant and duration of chemotherapy of more than six cycles correlated significantly with the incidence of CIA (P = 0.03). Conclusions: The major implication of this analysis is that the timing of treatment within the menstrual cycle may potentially modulate the onset of CIA. This work and its future confirmation using prospective randomized trials would be useful in predicting the likelihood of CIA and in counseling breast cancer patients, especially those with a good prognosis who benefit less from chemical castration.

Original languageEnglish
Pages (from-to)1065-1071
Number of pages7
JournalAnnals of Oncology
Volume15
Issue number7
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Amenorrhea
Menstrual Cycle
Breast Neoplasms
Drug Therapy
Incidence
Therapeutics
Follicular Phase
Menstruation
Luteal Phase
Castration
Counseling
Multivariate Analysis

Keywords

  • Adjuvant chemotherapy
  • Amenorrhea
  • Early breast cancer
  • Menstrual cycle phase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. / Di Cosimo, S.; Alimonti, A.; Ferretti, Gia; Sperduti, I.; Carlini, P.; Papaldo, P.; Fabi, A.; Gelibter, A.; Ciccarese, M.; Giannarelli, D.; Mandalà, M.; Milella, M.; Ruggeri, E. M.; Cognetti, F.

In: Annals of Oncology, Vol. 15, No. 7, 07.2004, p. 1065-1071.

Research output: Contribution to journalArticle

Di Cosimo, S. ; Alimonti, A. ; Ferretti, Gia ; Sperduti, I. ; Carlini, P. ; Papaldo, P. ; Fabi, A. ; Gelibter, A. ; Ciccarese, M. ; Giannarelli, D. ; Mandalà, M. ; Milella, M. ; Ruggeri, E. M. ; Cognetti, F. / Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. In: Annals of Oncology. 2004 ; Vol. 15, No. 7. pp. 1065-1071.
@article{f9c98d7bed574e83bc404979e7cc8f00,
title = "Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer",
abstract = "Background: The aim of this study was to characterize the factors associated with chemotherapy-induced amenorrhea (CIA) and to examine whether the phase of the menstrual cycle at chemotherapy start could affect the rate of CIA in premenopausal women with early breast cancer. Methods: CIA was defined as the cessation of menses for at least 3 months during or after chemotherapy. Menstrual phase was defined as days 1-6, follicular phase as days 7-14, luteal phase as days 15-20 and premenstrual phase as days 21-28. Univariate and multivariate predictors of CIA were examined. Results: Among 111 premenopausal women, univariate analysis showed a higher incidence of CIA in patients treated in the follicular phase rather than in other menstrual cycle phases (67.6{\%} compared with 45.5{\%}; P = 0.03). The rate of CIA increased with age: 65.2{\%} and 45.8{\%} in patients aged >42 and ≤42 years, respectively (P = 0.05). Upon multivariate analysis these differences remained statistically significant and duration of chemotherapy of more than six cycles correlated significantly with the incidence of CIA (P = 0.03). Conclusions: The major implication of this analysis is that the timing of treatment within the menstrual cycle may potentially modulate the onset of CIA. This work and its future confirmation using prospective randomized trials would be useful in predicting the likelihood of CIA and in counseling breast cancer patients, especially those with a good prognosis who benefit less from chemical castration.",
keywords = "Adjuvant chemotherapy, Amenorrhea, Early breast cancer, Menstrual cycle phase",
author = "{Di Cosimo}, S. and A. Alimonti and Gia Ferretti and I. Sperduti and P. Carlini and P. Papaldo and A. Fabi and A. Gelibter and M. Ciccarese and D. Giannarelli and M. Mandal{\`a} and M. Milella and Ruggeri, {E. M.} and F. Cognetti",
year = "2004",
month = "7",
doi = "10.1093/annonc/mdh266",
language = "English",
volume = "15",
pages = "1065--1071",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer

AU - Di Cosimo, S.

AU - Alimonti, A.

AU - Ferretti, Gia

AU - Sperduti, I.

AU - Carlini, P.

AU - Papaldo, P.

AU - Fabi, A.

AU - Gelibter, A.

AU - Ciccarese, M.

AU - Giannarelli, D.

AU - Mandalà, M.

AU - Milella, M.

AU - Ruggeri, E. M.

AU - Cognetti, F.

PY - 2004/7

Y1 - 2004/7

N2 - Background: The aim of this study was to characterize the factors associated with chemotherapy-induced amenorrhea (CIA) and to examine whether the phase of the menstrual cycle at chemotherapy start could affect the rate of CIA in premenopausal women with early breast cancer. Methods: CIA was defined as the cessation of menses for at least 3 months during or after chemotherapy. Menstrual phase was defined as days 1-6, follicular phase as days 7-14, luteal phase as days 15-20 and premenstrual phase as days 21-28. Univariate and multivariate predictors of CIA were examined. Results: Among 111 premenopausal women, univariate analysis showed a higher incidence of CIA in patients treated in the follicular phase rather than in other menstrual cycle phases (67.6% compared with 45.5%; P = 0.03). The rate of CIA increased with age: 65.2% and 45.8% in patients aged >42 and ≤42 years, respectively (P = 0.05). Upon multivariate analysis these differences remained statistically significant and duration of chemotherapy of more than six cycles correlated significantly with the incidence of CIA (P = 0.03). Conclusions: The major implication of this analysis is that the timing of treatment within the menstrual cycle may potentially modulate the onset of CIA. This work and its future confirmation using prospective randomized trials would be useful in predicting the likelihood of CIA and in counseling breast cancer patients, especially those with a good prognosis who benefit less from chemical castration.

AB - Background: The aim of this study was to characterize the factors associated with chemotherapy-induced amenorrhea (CIA) and to examine whether the phase of the menstrual cycle at chemotherapy start could affect the rate of CIA in premenopausal women with early breast cancer. Methods: CIA was defined as the cessation of menses for at least 3 months during or after chemotherapy. Menstrual phase was defined as days 1-6, follicular phase as days 7-14, luteal phase as days 15-20 and premenstrual phase as days 21-28. Univariate and multivariate predictors of CIA were examined. Results: Among 111 premenopausal women, univariate analysis showed a higher incidence of CIA in patients treated in the follicular phase rather than in other menstrual cycle phases (67.6% compared with 45.5%; P = 0.03). The rate of CIA increased with age: 65.2% and 45.8% in patients aged >42 and ≤42 years, respectively (P = 0.05). Upon multivariate analysis these differences remained statistically significant and duration of chemotherapy of more than six cycles correlated significantly with the incidence of CIA (P = 0.03). Conclusions: The major implication of this analysis is that the timing of treatment within the menstrual cycle may potentially modulate the onset of CIA. This work and its future confirmation using prospective randomized trials would be useful in predicting the likelihood of CIA and in counseling breast cancer patients, especially those with a good prognosis who benefit less from chemical castration.

KW - Adjuvant chemotherapy

KW - Amenorrhea

KW - Early breast cancer

KW - Menstrual cycle phase

UR - http://www.scopus.com/inward/record.url?scp=4143052526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143052526&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh266

DO - 10.1093/annonc/mdh266

M3 - Article

VL - 15

SP - 1065

EP - 1071

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -